| 产品描述: | Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC50 values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity. |
| 靶点: |
PI3Kα:0.2 nM (IC50); PI3Kβ:168 nM (IC50); PI3Kγ:90 nM (IC50); PI3Kδ:49 nM (IC50) |
| 体外研究: |
Vulolisib (10, 30 and 60 mg/kg; IG; daily for 7days) exhibits better tolerance and exposure than Inavolisib[1]. Vulolisib (10mg/kg; PO; daily for 19 days) inhibits tumor growth with TGI of 132%[1]. Vulolisib (5 mg/kg; IG, single dosage) exhibits favorable pharmacokinetic property[1]. Pharmacokinetic Parameters of Vulolisib in male Balb/c mice[1]. |
| 体内研究: |
Vulolisib has antiproliferative activity against PI3Kα-mutant cell lines HCC1954 (H1047R), HGC-27 (E542K) and MKN1 (E545K) with IC50s of 21 nM, 60 nM and 40 nM, respectively. |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.362 ml |
11.808 ml |
23.616 ml |
| 5 mM |
0.472 ml |
2.362 ml |
4.723 ml |
| 10 mM |
0.236 ml |
1.181 ml |
2.362 ml |
| 50 mM |
0.047 ml |
0.236 ml |
0.472 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |